Table 5.
eGFR and UP/C levels at weeks 0, 26, 52, and 78 in 20 patients responding to MMF/DEX
| Week | eGFR and UP/C Level | Change (wk) | % Change in eGFR and UP/C | ||||
|---|---|---|---|---|---|---|---|
| eGFR mean ± SD (ml/min per 1.73 m2) | UP/C median (10th–90th percentiles) (mg/mg) | eGFR mean ± SD (%) | P Value | UP/C median (10th–90th percentiles) (%) | P Value | ||
| 0 | 122.6±50.7 | 3.6 (1.1–9.6) | 0–26 | +0.8±23.1 | 0.88 | −76.2 (−91.9 to −59.7) | <0.001 |
| 26 | 119.7±46.3 | 0.8 (0.2–1.5) | 0–52 | +7.0±25.7 | 0.24 | −82.7 (−97.0 to −30.4) | <0.001 |
| 52 | 128.9±57.0 | 0.5 (0.1–2.6) | 0–78 | +3.8±28.5 | 0.56 | −80.3 (−94.5 to −0.7) | <0.001 |
| 78 | 126.1±58.9 | 0.8 (0.1–3.3) | 52–78 | −2.6±16.6 | 0.50 | +25.0 (−50.2 to 268.3) | 0.06 |
MMF/DEX, mycophenolate mofetil/dexamethasone; eGFR, estimated GFR; UP/C, urinary protein/creatinine.